Atea Pharmaceuticals, Inc. (AVIR)
- Previous Close
2.9600 - Open
2.9100 - Bid 2.7500 x 500
- Ask 2.8800 x 500
- Day's Range
2.7900 - 2.9500 - 52 Week Range
2.6000 - 4.1450 - Volume
450,137 - Avg. Volume
352,000 - Market Cap (intraday)
239.623M - Beta (5Y Monthly) 0.17
- PE Ratio (TTM)
-- - EPS (TTM)
-2.0000 - Earnings Date May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.50
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
ateapharma.comRecent News: AVIR
View More
Performance Overview: AVIR
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AVIR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AVIR
View MoreValuation Measures
Market Cap
239.62M
Enterprise Value
-213.46M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.55
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-15.60%
Return on Equity (ttm)
-33.88%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-168.38M
Diluted EPS (ttm)
-2.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
454.72M
Total Debt/Equity (mrq)
0.37%
Levered Free Cash Flow (ttm)
-39.55M